Literature DB >> 797491

Bioavailability of drugs: the digoxin dilemma.

D J Greenblatt, T W Smith, J Koch-Weser.   

Abstract

The absorption of oral digoxin preparations has been a topic of much concern during the last 5 years. The completeness of digoxin absorption is proportional to the area under the serum concentration time curve and to the urinary excretion of digoxin after single doses. During chronic therapy the completeness of absorption is proportional to these values and also to the steady state serum concentration. Determination of absolute bioavailability of a given digoxin preparation requires a comparative study using intravenous digoxin as a standard. Oral digoxin solutions are incompletely absorbed, but have biological availability greater than or equal to that of tablets. The absorption of digoxin tablets depends upon their dissolution rate which in turn is related to drug particle size. Digoxin tablets with small drug particles have rapid rates of dissolution and can be absorbed as completely as oral solutions. The bioavailability of digoxin from tablets can be influenced by changes in gastro-intestinal motility, malabsorption syndromes, and by co-administration of food or other drugs. New regulations now insure that all marketed digoxin tablet preparations have satisfactory bioavailability. Problems with biological availability at present are unlikely to account for unexpected clinical results during digoxin therapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 797491     DOI: 10.2165/00003088-197601010-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  97 in total

Review 1.  Appraisal of digoxin bioavailability and pharmacokinetics in relation to cardiac therapy.

Authors:  J G Wagner
Journal:  Am Heart J       Date:  1974-08       Impact factor: 4.749

Review 2.  Digitalis. I.

Authors:  T W Smith; E Haber
Journal:  N Engl J Med       Date:  1973-11-01       Impact factor: 91.245

3.  Recognition of variable bioavailability as an international problem: a review of the earlier studies.

Authors:  A D Munro-Faure; A S Fowle; J Fox; B F Johnson; S Lader
Journal:  Postgrad Med J       Date:  1974-11       Impact factor: 2.401

4.  The dissolution rate of digoxin tablets on the U.K. market: the scale of the problem.

Authors:  D A Cowan; A H Beckett
Journal:  Postgrad Med J       Date:  1974-11       Impact factor: 2.401

5.  The gastrointestinal absorption of digoxin in seven patients with gastric or small intestinal reconstructions.

Authors:  B Beermann; K Hellström; A Rosén
Journal:  Acta Med Scand       Date:  1973-04

6.  Identification by gas chromatography-mass spectroscopy of dihydrodigoxin--a metabolite of digoxin in man.

Authors:  E Watson; D R Clark; S M Kalman
Journal:  J Pharmacol Exp Ther       Date:  1973-02       Impact factor: 4.030

7.  Therapeutic non-equivalence of digoxin tablets in the United Kingdom: correlation with tablet dissolution rate.

Authors:  T R Shaw; K Raymond; M R Howard; J Hamer
Journal:  Br Med J       Date:  1973-12-29

8.  The absorption of orally administered (12 - 3 H)digoxin in man.

Authors:  B Beermann; K Hellström; A Rosén
Journal:  Clin Sci       Date:  1972-10       Impact factor: 6.124

9.  Assessment of methodology in single-dose studies of digoxin bioavailability.

Authors:  D J Greenblatt; D W Duhme; J Koch-Weser; T W Smith
Journal:  Pharmacology       Date:  1976       Impact factor: 2.547

10.  Absorption of digoxin in children with cystic fibrosis.

Authors:  A J Moss; S Finkelstein; C Crudup; G A Young; R R Dooley; A B Osher
Journal:  J Pediatr       Date:  1975-02       Impact factor: 4.406

View more
  21 in total

1.  Bioavailability of beta-acetyldigoxin after single and repeated doses of tablets and solution.

Authors:  U Klotz; K H Antonin; P R Bieck
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

2.  Bioavailability assessment: methods to estimate total area (AUC O to infinity) and total amount excreted (A infinity e) and importance of blood and urine sampling scheme with application to digoxin.

Authors:  J G Wagner; J W Ayres
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Prediction of digoxin dose requirements.

Authors:  S M Dobbs; G E Mawer
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

Review 4.  Drug interactions with digitalis glycosides.

Authors:  P F Binnion
Journal:  Drugs       Date:  1978-05       Impact factor: 9.546

5.  Effect of dose on bioavailability of oral digoxin.

Authors:  H R Ochs; G Bodem; D J Greenblatt
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

Review 6.  Plasma concentrations in the control of drug therapy.

Authors:  L B Jellett
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of digoxin.

Authors:  E Iisalo
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of digoxin in infants.

Authors:  G Wettrell; K E Andersson
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

9.  Absorption of digoxin in severe right heart failure.

Authors:  E E Ohnhaus; S Vozeh; E Nuesch
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

10.  Pharmacokinetics of digoxin in pregnancy.

Authors:  A M Luxford; G S Kellaway
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.